This legislation aims to streamline the approval process for biosimilar biological products, which are medications similar to already approved biological products. The primary goal is to reduce the clinical study requirements that sponsors must meet to obtain licensure, thereby facilitating quicker market access for these products. Key provisions include significant changes to the requirements for clinical studies.